Actelion presented controversial results of CI of a new antibiotic

news

Actelion's experimental antibacterial agent cadazolid (cadazolid) failed to reach the primary endpoints of the evaluation in one Phase III clinical trial, but it proved effective in another, identical, test. It is reported Reuters.
Actelion was told that the drug reached its primary endpoint - getting rid of diarrhea and the need for further drug therapy in the IMPACT 1 study, but could not demonstrate the same result in a similar IMPACT 2 study.
The promising antibiotic cabazolid became one of the main reasons for buying Actonion's Johnson & Johnson for $ 30 billion. Currently, the drug is being studied as an agent for the treatment of drug-resistant diarrhea associated with Clostridium difficile.

A source:

Remedium